PEDIATRIC ADVIL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PEDIATRIC ADVIL (PEDIATRIC ADVIL).
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
| Metabolism | Primarily hepatic via cytochrome P450 2C9 (CYP2C9) isoenzyme. Metabolites are excreted renally. |
| Excretion | Renal excretion of conjugated metabolites (glucuronides and sulfates) accounts for >90% of an administered dose, with <1% excreted unchanged. Biliary/fecal elimination is minimal (<5%). |
| Half-life | Terminal elimination half-life is approximately 2-4 hours in children. Clinical context: rapid clearance; requires frequent dosing every 6-8 hours for sustained antipyretic/analgesic effect. |
| Protein binding | >99% bound to albumin at therapeutic concentrations. |
| Volume of Distribution | Approximately 0.12-0.2 L/kg in children. Clinical meaning: low Vd indicates limited extravascular distribution consistent with high protein binding. |
| Bioavailability | Oral: 80-100% (rapidly absorbed). |
| Onset of Action | Oral: 15-30 minutes following ingestion; peak effect at 1-2 hours. |
| Duration of Action | Antipyretic/analgesic: 4-8 hours depending on dose. Clinical note: duration is dose-dependent; higher doses extend duration but increase adverse event risk. |
Ibuprofen 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | GFR 30-59 mL/min: no adjustment; GFR 15-29 mL/min: avoid use; GFR <15 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or avoid; Child-Pugh C: contraindicated. |
| Pediatric use | 6 months to 12 years: 5-10 mg/kg/dose orally every 6-8 hours as needed; maximum 40 mg/kg/day or 1000 mg/day, whichever is less. |
| Geriatric use | Start at lower end of dosing range (200 mg every 6-8 hours); monitor renal function and gastrointestinal tolerance; avoid long-term use if possible. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PEDIATRIC ADVIL (PEDIATRIC ADVIL).
| Breastfeeding | Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01-0.02). Considered compatible with breastfeeding due to low infant dose (<1% of maternal weight-adjusted dose). |
| Teratogenic Risk | First trimester: Association with increased risk of miscarriage and congenital malformations (cardiac, gastroschisis). Second trimester: Risk of oligohydramnios and premature closure of ductus arteriosus. Third trimester: Avoid due to risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, and necrotizing enterocolitis. |
■ FDA Black Box Warning
NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk.
| Serious Effects |
["Patients with known hypersensitivity to ibuprofen or any component of the formulation","Patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs","Patients with severe renal impairment (e.g., in the setting of volume depletion)","Patients with active peptic ulcer disease or GI bleeding","In the setting of coronary artery bypass graft (CABG) surgery","Neonates (avoid use in infants less than 6 months of age unless directed by a physician)"]
| Precautions | ["Cardiovascular thrombotic events, including myocardial infarction and stroke, can occur with NSAID use. Risk increases with duration of use and in patients with cardiovascular risk factors.","Gastrointestinal events: risk of GI bleeding, ulceration, and perforation.","Renal effects: can cause renal papillary necrosis and other renal injury; use with caution in patients with renal impairment or dehydration.","Anaphylactoid reactions: may occur in patients with aspirin sensitivity.","Hepatic effects: borderline elevations of liver tests may occur; discontinue if signs of hepatic injury develop.","Hematological effects: may inhibit platelet aggregation and prolong bleeding time.","Fluid retention and edema: use with caution in patients with hypertension or heart failure."] |
Loading safety data…
| Fetal Monitoring | Maternal: Renal function, blood pressure, gastrointestinal symptoms. Fetal: Ultrasound for oligohydramnios and ductus arteriosus patency if used after 20 weeks gestation. |
| Fertility Effects | Reversible inhibition of ovulation and luteal phase defects due to prostaglandin synthesis inhibition. Effects are transient and resolve upon discontinuation. |